Takeda and AC Immune Collaborate for ACI-24.060 to Treat Alzheimer’s Disease
Shots:
- Takeda & AC Immune have entered into an exclusive, worldwide option & license agreement to develop ACI-24.060, currently under P-Ib/II (ABATE) study to assess its safety, tolerability, immunogenicity & PD effects for prodromal Alzheimer’s disease & Down syndrome
- As per the agreement, AC Immune will obtain $100M upfront, an aggregate of up to ~$2.1B for development, commercial & sales-based milestones as well as option exercise fee, plus double-digit global net-sales based tiered royalties
- Furthermore, AC Immune will conclude the ABATE study, while Takeda will fund and carry out all future clinical development, global regulatory activities & commercialization
Ref: Takeda | Image: Takeda
Related News:- AC Immune Reports Results of ACI-24.060 in P-Ib/II Trial for the Treatment of Alzheimer’s Disease and Down Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
